Chikungunya virus vaccine - Themis Bioscience

Drug Profile

Chikungunya virus vaccine - Themis Bioscience

Alternative Names: Measles-vectored Chikungunya vaccine; MV-CHIK

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Themis Bioscience
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chikungunya virus infections

Most Recent Events

  • 29 Dec 2016 National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I trial in Chikungunya virus infections (Prevention) in USA (IM) (NCT03028441)
  • 02 Aug 2016 Phase-II clinical trials in Chikungunya virus infections (Prevention) in Austria (IM) (EudraCT2015-004037-26)
  • 19 Jan 2016 Themis Bioscience completes a phase-I trial in Chikungunya virus infections (prevention) in Austria (Parenteral) prior to January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top